Article

Aspheric IOL offers better contrast sensitivity

In a prospective, randomized, contralateral study of 75 adults, eyes in which an aspheric IOL (AcrySof IQ model SN60WF, Alcon Laboratories) had been implanted demonstrated better mesopic contrast sensitivity, significantly less spherical aberration, and significantly less total higher-order aberrations compared with eyes in which a standard spherical IOL (AcrySof model SA60AT, Alcon Laboratories) had been implanted. Cumulative uncorrected visual acuity and best-corrected visual acuity were equivalent between both groups.

Key Points

Chicago-Eyes in which an aspheric IOL (AcrySof IQ model SN60WF, Alcon Laboratories) had been implanted demonstrated superior contrast sensitivity and significantly less spherical aberration than eyes in which a standard spherical IOL (AcrySof model SA60AT, Alcon Laboratories) had been implanted, said W. Andrew Maxwell, MD, PhD, speaking here at American Society of Cataract and Refractive Surgery annual meeting.

Dr. Maxwell, a private practitioner in Fresno, CA, based his comments on findings from a prospective, randomized, observer- and subject-masked multicenter study. He and his colleagues who participated in the study followed 75 patients who had the aspheric IOL implanted in one eye and the spherical IOL implanted in the other.

The postoperative follow-up visits at 90 and 120 days (after the second eye surgery) included measurement of uncorrected visual acuity (UCVA) and best-corrected visual acuity (BCVA), spherical aberration, contrast sensitivity under mesopic conditions with and without glare (using the CSV-1000 chart, Vector Vision), and root mean square (RMS) values of total higher-order aberrations (HOAs).

"The mean contrast sensitivity with the aspheric lens was statistically significantly better at 6 cycles per degree (cpd), both with and without glare," Dr. Maxwell said.

Measurements of mean contrast sensitivity at 6 cpd under mesopic conditions without glare were 1.58 ± 0.40 log units (p = 0.0048) for the aspheric lens, compared with 1.47 ± 0.46 log units for the spherical lens. The aspheric lens also performed significantly better under the same conditions with glare (1.44 ± 0.50 log units, p = 0.0132) compared with the spherical lens (1.34 ± 0.52 log units)

Mean spherical aberration values were significantly lower for the aspheric lens. "Mean spherical aberration with the aspheric lens was 0.12, which is what this lens is intended to end up with," Dr. Maxwell said.

Analyses of total HOAs revealed significantly lower RMS values for the aspheric lens compared with the spherical controls.

"In this study, the aspheric lens demonstrated better mesopic contrast sensitivity, significantly less spherical aberration, and significantly less total HOAs than the standard spherical lens," Dr. Maxwell said.

The aspheric lenses may have additional benefits not shown in the data gathered in this study, he added.

"We conducted very elaborate night-driving simulation studies and found that the eyes that had the aspheric lens performed significantly better than the eyes that had the regular spherical lens," he concluded.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.